First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy presented at International Myology 2024 Congress
…
(read more)Genethon will introduce its latest advances in gene therapy research in multiple presentations at the International Myology 2024 Congress
…
(read more)Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases
…
(read more)Clinical results of the gene therapy trial in myotubular myopathy : efficacy on respiratory and motor functions in this extremely severe disease, challenges ahead
…
(read more)The Latest Research of 14 Généthon Scientists to be Featured at the European Society of Gene & Cell Therapy’s 30th Annual Congress, Oct. 24-27, 2023, in Brussels, Belgium
…
(read more)First results of Crigler-Najjar clinical trial published in New England Journal of Medicine
…
(read more)Genethon and Thales collaborate on artificial intelligence to improve bioproduction efficiency
…
(read more)Genethon’s R&D to be Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 16-20, 2023, in Los Angeles, CA
…
(read more)ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis (ALS)
…
(read more)Crigler-Najjar syndrome: Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy for patients with anti-AAV antibodies
…
(read more)Crigler-Najjar Syndrome: Genethon obtains PRIME priority drug status from the EMA for its gene therapy
…
(read more)Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
…
(read more)Genethon’s Latest Research, Including Advances in Gene Editing and AAV Delivery Vectors for Gene Therapy, to be Featured at European Society for Gene and Cell Therapy, Oct. 11-14, 2022
The gene therapy pioneering organization’s scientists will make multiple presentations on research aimed at curing rare diseases.
(read more)First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9
Study to treat FKRP-related limb-girdle muscular dystrophy type 2I/R9 represents 30 years of research and is being conducted by Genethon spinout Atamyo Therapeutics.
(read more)